stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) EPS (diluted)
Dr. Reddy's Laboratories Ltd's EPS (diluted) for fiscal 2026 was $0.55, down 30.4% from $0.79 in fiscal 2025. Over the twelve months to 30 September 2026 it was $0.33. Over the past ten years it has ranged from $0.18 (fiscal 2018) to $0.80 (fiscal 2024); the current reading is higher than 75% of that period. Dr. Reddy's Laboratories Ltd ranks 24th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | $0.55 | (30.38%) |
| FY2025 | $0.79 | (1.50%) |
| FY2024 | $0.80 | 21.52% |
| FY2023 | $0.66 | 76.47% |
| FY2022 | $0.37 | 19.11% |
| FY2021 | $0.31 | 0.64% |
| FY2020 | $0.31 | (4.88%) |
| FY2019 | $0.33 | 78.26% |
| FY2018 | $0.18 | (17.12%) |
| FY2017 | $0.22 | (37.29%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.12 | 100.00% |
| Jun 2026 | $0.06 | — |
| Mar 2026 | −$0.01 | — |
| Dec 2025 | $0.16 | (15.79%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | $6.74 |
| LNTH Lantheus Holdings, Inc. compare | $4.06 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $1.30 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $0.52 |
| RDY Dr. Reddy's Laboratories Ltd | $0.33 |
| ALKS Alkermes plc compare | −$0.01 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| VTRS Viatris Inc. compare | −$0.53 |
| HIMS Hims & Hers Health, Inc. compare | −$0.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RDY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement